Altfest L J & Co. Inc. Purchases Shares of 4,397 IQVIA Holdings Inc. $IQV

Altfest L J & Co. Inc. acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to its most recent filing with the SEC. The firm acquired 4,397 shares of the medical research company’s stock, valued at approximately $835,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Verdence Capital Advisors LLC bought a new stake in shares of IQVIA during the second quarter worth $3,612,000. Amundi lifted its holdings in IQVIA by 46.3% during the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after buying an additional 405,250 shares in the last quarter. Act Two Investors LLC purchased a new stake in IQVIA in the 2nd quarter valued at about $26,528,000. Diversified Trust Co grew its stake in IQVIA by 57.2% in the 3rd quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after acquiring an additional 15,487 shares in the last quarter. Finally, Patton Fund Management Inc. purchased a new position in shares of IQVIA during the second quarter worth approximately $231,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IQV. Truist Financial reissued a “buy” rating and issued a $265.00 price objective (up previously from $235.00) on shares of IQVIA in a research note on Wednesday, October 29th. Morgan Stanley increased their price target on IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Citigroup lifted their price objective on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a report on Wednesday, October 29th. JPMorgan Chase & Co. raised their target price on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Finally, Barclays set a $230.00 price target on shares of IQVIA in a research report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $243.19.

IQVIA Price Performance

IQV stock opened at $225.48 on Friday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $234.29. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock has a market cap of $38.40 billion, a price-to-earnings ratio of 30.93, a price-to-earnings-growth ratio of 2.29 and a beta of 1.36. The business has a fifty day moving average of $222.00 and a two-hundred day moving average of $197.49.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.